10-QPeriod: Q2 FY2005

IDEXX LABORATORIES INC /DE Quarterly Report for Q2 Ended Jun 30, 2005

Filed August 3, 2005For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported a solid performance for the second quarter and first half of 2005, demonstrating revenue growth across its key segments: Companion Animal Group (CAG), Water, and Food Diagnostics Group (FDG). Total revenue increased by 17% year-over-year for the quarter to $160.6 million and by 16% for the first half to $313.1 million. This growth was primarily driven by strong performance in laboratory and consulting services within CAG, alongside contributions from acquired businesses. While gross profit saw an increase, the gross profit margin slightly declined due to higher service costs and a shift in sales mix towards lower-margin products. Operating income decreased year-over-year for the quarter, impacted by increased operating expenses related to sales and marketing, general and administrative costs, and R&D, partly due to integration costs from recent acquisitions. However, the company maintained a strong cash position and generated positive cash flow from operations, indicating sound financial health.

Key Highlights

  • 1Total revenue for the quarter ended June 30, 2005, increased 17% to $160.6 million compared to $137.4 million in the prior year period.
  • 2Companion Animal Group (CAG) revenue grew 16.5% year-over-year for the quarter, driven significantly by a 41.8% increase in laboratory and consulting services.
  • 3Gross profit increased 11.9% to $80.6 million for the quarter, although the gross profit margin slightly decreased from 52.4% to 50.2%.
  • 4Operating income for the quarter decreased by 7.0% to $28.9 million from $31.1 million in the prior year, impacted by increased operating expenses.
  • 5Net income for the quarter was $19.9 million, or $0.59 per diluted share, a decrease from $23.9 million, or $0.66 per diluted share, in the prior year.
  • 6The company generated $38.1 million in cash flow from operating activities for the first six months of 2005.
  • 7IDEXX continued to repurchase its common stock, with $50.4 million spent on treasury stock purchases in the first six months of 2005.

Frequently Asked Questions

Revenue growth was primarily driven by the Companion Animal Group (CAG), which saw a significant increase in laboratory and consulting services. Acquisitions made in 2004 and early 2005 also contributed to the revenue growth across various segments, particularly in CAG and Food Diagnostics Group (FDG).

Operating income decreased due to a significant increase in operating expenses. This increase was mainly attributed to higher sales and marketing expenses, general and administrative costs (including integration costs from acquisitions), and research and development spending. These investments were made to support revenue growth and strategic initiatives.

The company maintains a strong financial position with $131.0 million in cash and cash equivalents and short-term investments as of June 30, 2005. Operating cash flow remained positive, indicating the company's ability to fund its operations and growth strategies. The company believes its current resources are sufficient to meet its financial obligations.

The company is currently evaluating the impact of SFAS No. 123(R) 'Share-Based Payment,' which is expected to change how stock-based compensation is recognized. They plan to adopt this standard effective January 1, 2006. For the current period, accounting policies remain consistent with the prior year's annual report, with no material changes impacting the financial statements.